ClinicalTrials.gg
CompletedNCT00840216Updated Aug 19, 2024Results posted

Clarithromycin 500 mg Extended Release Tablets Under Non-Fasting Conditions.

A Phase 1 interventional study of Clarithromycin ER 500 mg tablets and BIAXIN® XL 500 mg tablets in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare the relative bioequivalence of a test clarithromycin extended release formulation to an equivalent oral dose of the commercially available extended release clarithromycin in a test population of 22 adult subjects under fed conditions.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sex: Males or females who are surgically sterile or have been for at least 6 months; similar proportions of each preferred.
  • Age: At least 18 years.
  • Qualifying subjects must be in good health and physical condition as determined by medical history, complete physical examination, and laboratory tests, all obtained within four (4) weeks prior to study start. The subjects may not have a history of significant past illness expected to affect the investigation. The normal status of subjects will be confirmed by the following procedures:

    1. Laboratory Tests:

      , hematocrit, RBC, WBC, differential count, serum electrolytes (Nz, K, Cl), fasting blood glucose, BUN, ,m creatinine, , ALT, LD, alkaline phosphatase and urinalysis. , , , and drugs of abuse testing will be done for screening purposes only. Urine drugs of abuse testing will be repeated at each check-in. Female subjects will have a serum pregnancy test done at screening and a urine pregnancy test prior to each study period at check-in. Post-menopausal females will have an FSH (Follicle Stimulating Hormone) level performed to confirm post-menopausal status.

      Laboratory values which are greater than ±20% of the normal range will not qualify unless specifically accepted (with comment) by the Principal Investigator. Results of HIV, Hepatitis B, Hepatitis C, and drugs of abuse must be negative or non-reactive for the subject to qualify for the study.

A 12-lead electrocardiogram (ECG) will be obtained for all subjects. The original tracings, plus interpretation, will be included in the case report form packet.

  • Subjects must read and sign the Consent Form.

Exclusion criteria

Exclusion Criteria

  • Subjects not complying with the above inclusion criteria must be excluded from the study.
  • In addition, any one of the conditions listed below will exclude a subject from the study:

    1. History of treatment for alcoholism, substance abuse, or drug abuse within past 24 months.
    2. History of , stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
    3. History of treatment for any gastrointestinal disorder within the past 5 years.
    4. History of treatment for asthma within the past five (5) years.
    5. History of diarrhea within 24 hours prior to dosing.
    6. Females who are pregnant or lactating.
    7. History of to clarithromycin or any macrolide antibiotic.
  • Conditions upon screening which might contraindicate or require that caution be used in the administration of dexmethylphenidate hydrochloride, including:

    1. Sitting systolic blood pressure below 90 mm Hg, or diastolic pressure below 50 mm Hg.
    2. Heart rate less than 50 beats per minute after a 5-minute rest in a seated position.
  • Inability to read and/or sign the consent form.
  • Treatment with any other drug during the four (4) weeks prior to the initial dosing for this study.
  • Subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.
  • Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.). Three (3) consecutive months abstinence is required.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    1

    Drug: Clarithromycin ER 500 mg tablets

  • Active comparator
    2

    Drug: BIAXIN® XL 500 mg tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax - Maximum Observed Concentration

    Bioequivalence based on Cmax

    Time frame: Blood samples collected over 36 hour period

  2. AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

    Bioequivalence based on AUC0-inf

    Time frame: Blood samples collected over 36 hour period

  3. AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

    Bioequivalence based on AUC0-t

    Time frame: Blood samples collected over 36 hour period

07

Results

Posted Jul 21, 2009

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1111
Completed1111
Not completed00
Washout: 7 Days
Participant flow — Washout: 7 Days
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1111
Completed1011
Not completed10
Withdrew: Withdrawal by subject10
Second Intervention
Participant flow — Second Intervention
MilestoneClarithromycin (Test) FirstBiaxin® (Reference) First
Started1011
Completed1011
Not completed00

Outcome measures

PrimaryCmax - Maximum Observed Concentration

Bioequivalence based on Cmax

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng/mL
Cmax - Maximum Observed Concentration
ng/mLClarithromycinBiaxin®
Cmax - Maximum Observed Concentration1515.00 ± 533.7821464.10 ± 700.030
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 106.9Bioequivalence is established when the ratio of the mean falls within 80-125.
PrimaryAUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)

Bioequivalence based on AUC0-inf

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
ng*h/mLClarithromycinBiaxin®
AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)14449.3 ± 4684.1115699.8 ± 5991.11
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 92.7Bioequivalence is established when ratio of the mean falls within 80-125.
PrimaryAUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration

Bioequivalence based on AUC0-t

Time frame:
Blood samples collected over 36 hour period
Reported as:
Mean · ng*h/mL
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration
ng*h/mLClarithromycinBiaxin®
AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration14236.7 ± 4681.2815389.5 ± 5923.27
Statistical analysis
  • Clarithromycin vs Biaxin® · Test/ref ratio of ls means x 100: 93.0Bioequivalence is established when ratio of the mean falls within 80-125.

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
<=18 years000
Between 18 and 65 years101020
>=65 years112
Sex: Female, Male
Sex: Female, Male(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
Female5611
Male6511
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
Caucasian91019
Black213
Region of Enrollment
Region of Enrollment(participants)Clarithromycin (Test) FirstBiaxin® (Reference) FirstTotal
United States111122
08

Study locations

1 site
  • Gateway Medical Research Inc.
    Saint Charles, Missouri 63301, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Aug 2002 and a completion of Aug 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 6 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2009
First posted
Feb 10, 2009
Start
Aug 2002
Primary completionActual
Aug 2002
CompletionActual
Aug 2002
Results first posted
Jul 21, 2009
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00840216
First posted
Feb 10, 2009
Start date
Aug 2002
Primary completion
Aug 2002
Completion
Aug 2002
Results posted
Jul 21, 2009
Last update
Aug 19, 2024

Study contacts

Ali Ziaee, MD
principal investigator · Gateway Medical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clarithromycin

Start the discussion